Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection

Summary: The Omicron variant of SARS-CoV-2, first identified in South Africa and Botswana in November 2021, has rapidly spread globally with high transmissibility. It has an unprecedented number of mutations in its spike gene, leading to immune escape and reduced vaccine efficacy. The neutralizing and binding activity against Omicron varies among individuals with different vaccination and infection histories.

Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.